Webinar featuring our Formulation Scientist, Sydney Marchando, MS. & Nick Boylan, Ph.D., Director of Nucleic Acid Delivery.
Glioblastoma (GBM) is a malignant brain tumor that remains among the most formidable cancers.Despite a well-established standard of care of maximal surgical resection followed by radiotherapy plus concomitant temozolomide (TMZ), median survival remains approximately 15 months.
Our team presents the process of Nanosuspension for the novel Indirubin, for the potential treatment of Glioblastoma.